Verita Research Enters China Market Through License Of Its Polymer Delivery System
April 25, 2016
Singapore, 25 April 2016 – Verita Healthcare Group (“Verita”) has signed a licensing agreement with Auswell Limited and Acpharm HK Limited to commence clinical trials for the implementation of the Naltrexone time released medication in the China market.
Naltrexone is an opioid receptor antagonist. The primary indications for the use of Naltrexone are the management of opioid and alcohol addiction. Verita Research Pte Ltd has the unique delivery dose system, a controlled release depot that releases therapeutic levels of Naltrexone for a period of time makes the hospitalization period shorter and compliance much simpler as the patient isn’t faced with the daily decision of whether to take their dose of naltrexone or break out. The specialized formulation delivers Naltrexone at therapeutic levels for up to 30 days. The number of registered addicts in 2004 was 1.14 million (more than 75% of them heroin addicts), but the actual number is probably far higher. China faces substantial drug abuse problems that appear to be worsening with time. Opiate dependence is a major threat to the public health and social security of China because of its devastating medical effects, its impact on risk for HIV/AIDS and criminal behaviors, low rates of recovery and high rates of relapse. There is an urgent need to implement modern treatments for opiate dependence more widely in China. Comments: “Naltrexone time released delivery medication is a proven, safe and effective treatment to be used in the fight against opiate addiction in China”